Has CNS metastases or symptomatic CNS involvement
Symptomatic CNS involvement.
Symptomatic CNS metastases which are neurologically unstable or requiring increasing doses of steroids to control their CNS disease.
Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring steroids.
Subject has symptomatic CNS metastases.
Active (i.e., symptomatic or progressing) CNS metastases. Subjects with CNS metastases are eligible for the trial if:
Patient has symptomatic brain or CNS metastases
have known uncontrolled or symptomatic CNS metastases;
Subject has symptomatic CNS metastases.
Subject has symptomatic CNS metastases. Subjects with prior history of symptomatic CNS metastasis must have received treatment and be neurologically stable for at least  month prior to leukapheresis and lymphodepletion.
Symptomatic CNS metastases or CNS metastases requiring steroids
Suspected, known, or progressive CNS metastases (Imaging required only if participants are symptomatic)
Patients with symptomatic CNS metastases;
Patients with symptomatic CNS metastases.
Subjects with symptomatic CNS metastases.
Known uncontrolled or symptomatic CNS metastases
Patients with extensive advanced/metastatic, symptomatic visceral disease, or known uncontrolled or symptomatic CNS metastases
Known uncontrolled or symptomatic CNS metastases
CNS metastases that are symptomatic and /or requiring escalating doses of steroids.
Presence of symptomatic CNS lymphoma
Symptomatic OR
Symptomatic CNS disease
Subjects with symptomatic or unstable CNS metastases
CNS metastases that are symptomatic and /or requiring steroids.
Symptomatic CNS disease
Symptomatic CNS metastases
Symptomatic CNS metastases
Symptomatic CNS metastases
Symptomatic CNS metastases
Symptomatic CNS metastases
Have known active uncontrolled or symptomatic CNS metastases